A RANDOMIZED STUDY OF INTRAVENOUS BOLUS VERSUS CONTINUOUS INFUSION OF IFOSFAMIDE AND DOXORUBICIN WITH ORAL ETOPOSIDE FOR SMALL-CELL LUNG-CANCER

被引：7

作者：

ANDERSON, H ^{[1
]}

PRENDIVILLE, J ^{[1
]}

THATCHER, N ^{[1
]}

RADFORD, JA ^{[1
]}

SWINDELL, R ^{[1
]}

机构：

[1] CHRISTIE HOSP & HOLT RADIUM INST,DEPT MED STAT,MANCHESTER M20 9BX,LANCS,ENGLAND

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 1991年 / 117卷

关键词：

BOLUS; CONTINUOUS INFUSION; ORAL ETOPOSIDE; SMALL-CELL LUNG CANCER;

D O I：

10.1007/BF01613219

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

159 "poor risk" patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1, 3, 5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1-5, 15-19, and 29-33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P = 0.0007), and less nausea and vomiting (P = 0.03).

引用

页码：S139 / S140

页数：2